XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Note 8- Stock-based Compensation
3 Months Ended
Mar. 31, 2023
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

8.

Stock-Based Compensation

 

2015 Equity Plan

 

The 2015 Equity Plan provides for increases to the number of shares reserved for issuance thereunder each January 1 equal to 4.0% of the total shares of the Company’s common stock outstanding as of the immediately preceding December 31, unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 81,582 shares were added to the reserve as of January 1, 2023, which shares may be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the 2015 Equity Plan. As of March 31, 2023, there were 141,096 shares available for future issuance under the 2015 Equity Plan.

 

 

The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations and comprehensive loss for the periods indicated:

 

   

Three Months Ended

March 31,

 
   

2023

   

2022

 

Research and development

  $ 12,011     $ 58,892  

General and administrative

    109,360       219,239  

Total stock-based compensation expense

  $ 121,371     $ 278,131  

 

The following table summarizes the activity related to all stock option grants for the three months ended March 31, 2023:

 

   

Number of

Options

   

Weighted

average

exercise price

per share

   

Weighted

average

remaining

contractual life

(in years)

   

Aggregate

intrinsic

value

 

Balance at January 1, 2023

    140,040     $ 126.75                  

Granted

                           

Cancelled

    (35,993 )     20.13                  

Outstanding at March 31, 2023

    104,047     $ 163.64       7.99     $  

Exercisable at March 31, 2023

    78,533     $ 211.21       7.75     $  

Vested and expected to vest at March 31, 2023

    104,047     $ 163.64       7.99     $  

 

There were no options granted during the three months ended March 31, 2023. The total fair value of options vested during the three months ended March 31, 2023 and 2022 was $0.1 million and $0.2 million, respectively. No options were exercised during any of the periods presented. At March 31, 2023, there was $0.4 million of unrecognized compensation expense that will be recognized over a weighted-average period of 1.27 years.

 

Restricted Stock Unit Awards

 

The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of an RSU is equal to the fair market value price of the Company’s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.

 

The following table summarizes activity related to RSU awards during the period indicated:

 

   

Number of Units

   

Weighted average grant date fair value

 

Balance at January 1, 2023

    3,652     $ 36.49  

Vested (1)

    (742 )     33.72  

Outstanding at March 31, 2023

    2,910     $ 38.28  

 

(1) The RSUs vested during the three months ended March 31, 2023 were settled on a hybrid basis. The Company withheld 274 shares of common stock and, in lieu of delivering such shares, paid the RSU holder an amount in cash equal to the fair market value of such shares on the vesting date, representing the holder's approximate tax liability associated with the vesting.

 

 

The Company recognized approximately $14,000 and $16,000 in expense related to these awards during the three months ended March 31, 2023 and March 31, 2022, respectively. At March 31, 2023, there was $48,000 in unrecognized compensation cost that will be recognized over a weighted average period of 1.04 years.